Background: Nivolumab (Nivo) monotherapy has demonstrated clinical activity and
639P A phase II study of TAS-102 for advanced/recurrent esophageal cancer refractory/intolerable to standard therapies Background: There is no effective chemotherapy for patients with esophageal squamous cell carcinoma (ESCC) refractory or intolerant to 5-FU, platinum, and taxanes. TAS-102 is an oral combination drug of trifluridine and tipiracil hydrochloride. Our preclinical study showed that TAS-102 has antitumor activity against 5-FU resistant esophageal cancer cells. We conducted this study to evaluate the safety and efficacy of TAS-102 in ESCC patients who were refractory or intolerant to standard treatment (UMIN000019268). Methods: Patients with histologically proven advanced or recurrent ESCC, which had been refractory or intolerable to 5-FU, platinum, and taxanes, were eligible. Patients also had to satisfy following criteria: >20 years of age; ECOG performance status 0 or 1; adequate organ functions. TAS-102, 35 mg/m2 bid, was administered on days 1-5 and 8-12 for the first 2 weeks followed by 2-week rest. The regimen was repeated every 4 weeks until disease progression, serious adverse event, or refusal. Primary endpoint was progression-free survival rate at 3 months (PFS3). With expected PFS3 of 25% to 30% and the null hypothesis of 10% under 80% power and a one-sided significance level of 5%, 35 patients was needed. Results: A total of 42 patients were enrolled. 90% of the patients were male, 95% had distant metastasis, and 98% had target lesion (s). As of data cutoff, 34 events were observed. PFS3 was 15.4% (90% CI: 7.4%, 26.0%), which did not reject the null hypothesis. Median PFS and OS were 1.3 months and 4.5 months, respectively. Response rate was 0%, although 24% (10/42) of patients achieved stable disease. There were 3 patients not evaluable for response. Major treatment related adverse events of grade м3 were: neutrophil count decreased (48%), febrile neutropenia (7%), and appetite decreased (5%). No treatment related death was observed. Background: Esophageal adenocarcinoma (EAC) is a leading cause of cancer deaths, and current treatment options are limited. Cell cycle regulators CDK4 and CDK6 are progressively upregulated in EAC carcinogenesis and associated with poor prognosis. The modified Levrat model of esophagojejunostomy (EJ) in a rat has demonstrated well-documented utility for in vivo efficacy testing against de novo EAC. In the present study, we evaluate a dual CDK4/6 inhibitor, abemaciclib, for the treatment of EAC. Methods: Human EAC cell lines, OE33 and FLO1, were used to evaluated proliferation and apoptosis using BrdU and flow cytometry, respectively. EJ was performed on 38 Sprague-Dawley rats to induce gastroduodenoesophageal reflux and the subsequent development of EAC. At 36 weeks post-operatively, rats were randomized to receive IP abemaciclib at 26 mg/kg per day or placebo (acetate buffer) for 4 weeks. Drug efficacy was evaluated with MRI, endoscopic biopsy, gross histological evaluation, and CDK4/6 pathway expression by RT-PCR. 
